Investing.comDoubao · 实盘不做把握 7/10不做原因:无增量信息
北京时间·🕒 发布 21:36:35·⟳ 抓取 21:36:57 +22s·⚡ 决策 10-14 21:39:23 +2m26s·13.2 天前
Oncolytics（ONCY）宣布GOBLET I/II期完成入组，Cohort 4最终数据预计2026Q4读出
本次公告只有入组完成、拨款尾款时点和远期数据时间表，疗效信息均为此前已披露队列数据的定性重述（达预设标准、mOS超预期但无新数字），不构成可交易的短期催化；硬数据要等2026Q4（Cohort 4）和2027H1（Cohort 5）。市场用脚投票：消息当日盘中-7.2%，20日累计-37%，流动性极差（20日日均成交额约80万美元），无edge。无利空新事实，亦不构成做空理由。
📄 原文Investing.com↗ 原文
Oncolytics reports GOBLET study enrollment complete
U.S. consumer prices rise 3.7% year-on-year in September SAN DIEGO - Oncolytics Biotech Inc. (NASDAQ:ONCY) announced to…
不做 Oncolytics Biotech Inc.（ONCY.US）
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Oncolytics宣布GOBLET研究完成入组并重申远期数据时间表，属程序性进展、无新增定量数据；真正催化在数周乃至数月后，股价当日反跌7%且处下降通道、流动性极差，不做。
消息传播链
- 节点
关键理由
- 入组完成与达预设成功标准是定性里程碑，Cohort 4初步安全性/疗效数据早在ASCO GI 2025已公布，本次无新增硬数字
- 当日盘中股价-7.2%、20日-37%、13周轨迹100降至58，消息未引发任何正反馈，短期无预期差
主要风险
- Cohort 4最终数据若在Q4早于预期公布且mOS显著，可能引发微盘股脉冲行情（市值仅约0.6亿美元）
- Investing.com稿件标题误植为CPI内容且标注AI生成，存在转述失真或另有同名通稿的风险
反向证据
- 做多前查反向 · 来源 web · 日期 2026-10-12 · 影响 weakens
公司10月12日刚发布专利组合更新通稿，近期股价10月12日单日-15%、20日-37%，市场或在交易现金跑道/潜在摊薄担忧；本次拨款尾款金额未披露，无法证伪融资压力，做多风险收益差
检索:Oncolytics ONCY cash runway financing dilution October 2026 原文 ↗
先例如何影响了这次决策
对本次决策的影响:因无新增数据的程序性里程碑直接AVOID，未做event_study；微盘生物科技入组完成类公告历史上通常仅在伴随超预期疗效信息或融资动作时才有显著波动，与本案不符
方向:无可对照先例；本次结论不依赖先例
涨幅量级:不适用
形态:不适用
工具执行结果 · 成功 3 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 12 ms
{"result": "search_processed_events:agent query=`oncolytics biotech goblet study enrollment complete pelareorep | oncolytics pelareorep pancreatic cancer action network grant | oncy goblet cohort 4 anal carcinoma atezolizumab res`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agen - web_search 成功 doubao_search · 1,555 ms
豆包搜索结果（原始查询:Oncolytics Biotech GOBLET enrollment complete press release October 2026 pelareorep；API SearchType:web） - stock_quote 成功 stock_tools HTTP · 219 ms
{
原文全文
展开原文 · 1,898 字
U.S. consumer prices rise 3.7% year-on-year in September
SAN DIEGO - Oncolytics Biotech Inc. (NASDAQ:ONCY) announced today that enrollment in its GOBLET Phase 1/2 study has been completed and the company expects to receive its final grant payment from the Pancreatic Cancer Action Network this quarter.
The company stated it expects to report final results from Cohort 4, which evaluates pelareorep with atezolizumab in patients with second-line and later squamous cell anal carcinoma, in the fourth quarter of 2026. Initial results from Cohort 5, evaluating pelareorep-based therapy in combination with chemotherapy with and without atezolizumab in patients with first-line metastatic pancreatic ductal adenocarcinoma, are expected in the first half of 2027, according to a press release statement.
Thomas Heineman, Chief Medical Officer of Oncolytics, stated that each cohort that enrolled the required number of patients met its pre-specified success criteria for efficacy. He added that median overall survival in Cohort 4 exceeds expectations.
The GOBLET study is being conducted at 17 centers in Germany and managed by AIO-Studien-gGmbH. The co-primary endpoints are objective response rate and/or disease control rate and safety.
Oncolytics stated it is winding down the broader GOBLET study infrastructure while continuing treatment and follow-up of remaining patients. The company said it will use the clinical data to focus its strategy to combine pelareorep with a checkpoint inhibitor in gastrointestinal and additional tumors.
Pelareorep is an investigational immunotherapy that has been administered to over 1,200 patients. The company has received Fast Track designation from the U.S. Food and Drug Administration for pelareorep in colorectal, anal, and pancreatic cancer.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
SAN DIEGO - Oncolytics Biotech Inc. (NASDAQ:ONCY) announced today that enrollment in its GOBLET Phase 1/2 study has been completed and the company expects to receive its final grant payment from the Pancreatic Cancer Action Network this quarter.
The company stated it expects to report final results from Cohort 4, which evaluates pelareorep with atezolizumab in patients with second-line and later squamous cell anal carcinoma, in the fourth quarter of 2026. Initial results from Cohort 5, evaluating pelareorep-based therapy in combination with chemotherapy with and without atezolizumab in patients with first-line metastatic pancreatic ductal adenocarcinoma, are expected in the first half of 2027, according to a press release statement.
Thomas Heineman, Chief Medical Officer of Oncolytics, stated that each cohort that enrolled the required number of patients met its pre-specified success criteria for efficacy. He added that median overall survival in Cohort 4 exceeds expectations.
The GOBLET study is being conducted at 17 centers in Germany and managed by AIO-Studien-gGmbH. The co-primary endpoints are objective response rate and/or disease control rate and safety.
Oncolytics stated it is winding down the broader GOBLET study infrastructure while continuing treatment and follow-up of remaining patients. The company said it will use the clinical data to focus its strategy to combine pelareorep with a checkpoint inhibitor in gastrointestinal and additional tumors.
Pelareorep is an investigational immunotherapy that has been administered to over 1,200 patients. The company has received Fast Track designation from the U.S. Food and Drug Administration for pelareorep in colorectal, anal, and pancreatic cancer.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
2a1a1c256a· 2026-10-14 21:39 · doubao / doubao-seed-evolving-latest-version · 策略包2226518bfdee当前